APO Research
Talk to an analyst

APO RESEARCH · REPORT

Duloxetine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Duloxetine Market Outlook and Growth Opportunities 2026

22 December 2025193 pages

Choose your research edition.

Industry ResearchDuloxetine Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Duloxetine Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Duloxetine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Duloxetine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Duloxetine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Duloxetine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Duloxetine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Duloxetine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Duloxetine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Duloxetine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Duloxetine market include Teva, Sun Pharma, Eli Lilly, Zydus Pharmaceuticals, Jiangsu Nhwa Pharmaceutical, Torrent Pharmaceuticals, MACLEODS, Lupin and CSPC Ouyi Pharm, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Duloxetine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Duloxetine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Duloxetine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Duloxetine market.

Duloxetine Segment by Company

Teva

Sun Pharma

Eli Lilly

Zydus Pharmaceuticals

Jiangsu Nhwa Pharmaceutical

Torrent Pharmaceuticals

MACLEODS

Lupin

CSPC Ouyi Pharm

Breckenridge

Aurobindo Pharma

Apotex

Ajanta Pharma

Duloxetine Segment by Type

60mg Capsules

40mg Capsules

30mg Capsules

20mg Capsules

Duloxetine Segment by Application

Hospital

Drug store

Duloxetine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Duloxetine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Duloxetine key companies, revenue, market share, and recent developments.

3. To split the Duloxetine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Duloxetine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Duloxetine significant trends, drivers, influence factors in global and regions.

6. To analyze Duloxetine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duloxetine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Duloxetine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duloxetine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Duloxetine industry.

Chapter 3: Detailed analysis of Duloxetine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Duloxetine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Duloxetine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Duloxetine Industry Trends Table 2. Duloxetine Industry Drivers Table 3. Duloxetine Industry Opportunities and Challenges Table 4. Duloxetine Industry Restraints Table 5. Global Duloxetine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Duloxetine Revenue Share by Company (2021-2026) Table 7. Global Duloxetine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Duloxetine Key Company Manufacturing Base & Headquarters Table 9. Global Duloxetine Company, Product Type & Application Table 10. Global Duloxetine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Duloxetine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 60mg Capsules Table 15. Significant Companies of 40mg Capsules Table 16. Significant Companies of 30mg Capsules Table 17. Significant Companies of 20mg Capsules Table 18. Global Duloxetine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Duloxetine Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Duloxetine Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Duloxetine Sales Value Share by Type (2021-2026) Table 22. Global Duloxetine Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Drug store Table 25. Global Duloxetine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Duloxetine Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Duloxetine Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Duloxetine Sales Value Share by Application (2021-2026) Table 29. Global Duloxetine Sales Value Share by Application (2027-2032) Table 30. Global Duloxetine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Duloxetine Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Duloxetine Sales Value Share by Region (2021-2026) Table 33. Global Duloxetine Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Duloxetine Sales Value Share by Region (2027-2032) Table 35. Global Duloxetine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Duloxetine Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Duloxetine Sales Value Market Share by Country (2021-2026) Table 38. Global Duloxetine Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Duloxetine Sales Value Market Share by Country (2027-2032) Table 40. Teva Company Information Table 41. Teva Business Overview Table 42. Teva Duloxetine Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Teva Duloxetine Product Portfolio Table 44. Teva Recent Development Table 45. Sun Pharma Company Information Table 46. Sun Pharma Business Overview Table 47. Sun Pharma Duloxetine Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Sun Pharma Duloxetine Product Portfolio Table 49. Sun Pharma Recent Development Table 50. Eli Lilly Company Information Table 51. Eli Lilly Business Overview Table 52. Eli Lilly Duloxetine Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Eli Lilly Duloxetine Product Portfolio Table 54. Eli Lilly Recent Development Table 55. Zydus Pharmaceuticals Company Information Table 56. Zydus Pharmaceuticals Business Overview Table 57. Zydus Pharmaceuticals Duloxetine Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Zydus Pharmaceuticals Duloxetine Product Portfolio Table 59. Zydus Pharmaceuticals Recent Development Table 60. Jiangsu Nhwa Pharmaceutical Company Information Table 61. Jiangsu Nhwa Pharmaceutical Business Overview Table 62. Jiangsu Nhwa Pharmaceutical Duloxetine Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Jiangsu Nhwa Pharmaceutical Duloxetine Product Portfolio Table 64. Jiangsu Nhwa Pharmaceutical Recent Development Table 65. Torrent Pharmaceuticals Company Information Table 66. Torrent Pharmaceuticals Business Overview Table 67. Torrent Pharmaceuticals Duloxetine Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Torrent Pharmaceuticals Duloxetine Product Portfolio Table 69. Torrent Pharmaceuticals Recent Development Table 70. MACLEODS Company Information Table 71. MACLEODS Business Overview Table 72. MACLEODS Duloxetine Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. MACLEODS Duloxetine Product Portfolio Table 74. MACLEODS Recent Development Table 75. Lupin Company Information Table 76. Lupin Business Overview Table 77. Lupin Duloxetine Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Lupin Duloxetine Product Portfolio Table 79. Lupin Recent Development Table 80. CSPC Ouyi Pharm Company Information Table 81. CSPC Ouyi Pharm Business Overview Table 82. CSPC Ouyi Pharm Duloxetine Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. CSPC Ouyi Pharm Duloxetine Product Portfolio Table 84. CSPC Ouyi Pharm Recent Development Table 85. Breckenridge Company Information Table 86. Breckenridge Business Overview Table 87. Breckenridge Duloxetine Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Breckenridge Duloxetine Product Portfolio Table 89. Breckenridge Recent Development Table 90. Aurobindo Pharma Company Information Table 91. Aurobindo Pharma Business Overview Table 92. Aurobindo Pharma Duloxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Aurobindo Pharma Duloxetine Product Portfolio Table 94. Aurobindo Pharma Recent Development Table 95. Apotex Company Information Table 96. Apotex Business Overview Table 97. Apotex Duloxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Apotex Duloxetine Product Portfolio Table 99. Apotex Recent Development Table 100. Ajanta Pharma Company Information Table 101. Ajanta Pharma Business Overview Table 102. Ajanta Pharma Duloxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Ajanta Pharma Duloxetine Product Portfolio Table 104. Ajanta Pharma Recent Development Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Duloxetine Product Image Figure 2. Global Duloxetine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Duloxetine Market Size (2021-2032) & (US$ Million) Figure 4. Global Duloxetine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 60mg Capsules Image Figure 8. 40mg Capsules Image Figure 9. 30mg Capsules Image Figure 10. 20mg Capsules Image Figure 11. Global Duloxetine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Duloxetine Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Duloxetine Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Drug store Image Figure 16. Global Duloxetine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Duloxetine Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Duloxetine Sales Value Share by Application (2021-2032) Figure 19. Global Duloxetine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Duloxetine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Duloxetine Sales Value (2021-2032) & (US$ Million) Figure 22. North America Duloxetine Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Duloxetine Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Duloxetine Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Duloxetine Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Duloxetine Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Duloxetine Sales Value (2021-2032) & (US$ Million) Figure 28. South America Duloxetine Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Duloxetine Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Duloxetine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Duloxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Duloxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Duloxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • 60mg Capsules
  • 40mg Capsules
  • 30mg Capsules
  • 20mg Capsules
Applications
  • Hospital
  • Drug store
Companies covered
  • Teva
  • Sun Pharma
  • Eli Lilly
  • Zydus Pharmaceuticals
  • Jiangsu Nhwa Pharmaceutical
  • Torrent Pharmaceuticals
  • MACLEODS
  • Lupin
  • CSPC Ouyi Pharm
  • Breckenridge
  • Aurobindo Pharma
  • Apotex
  • Ajanta Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Duloxetine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Duloxetine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Duloxetine Market Dynamics
  1. 2.1 Duloxetine Industry Trends
  2. 2.2 Duloxetine Industry Drivers
  3. 2.3 Duloxetine Industry Opportunities and Challenges
  4. 2.4 Duloxetine Industry Restraints
3 Duloxetine Market by Company
  1. 3.1 Global Duloxetine Company Revenue Ranking in 2025
  2. 3.2 Global Duloxetine Revenue by Company (2021-2026)
  3. 3.3 Global Duloxetine Company Ranking (2024-2026)
  4. 3.4 Global Duloxetine Company Manufacturing Base and Headquarters
  5. 3.5 Global Duloxetine Company Product Type and Application
  6. 3.6 Global Duloxetine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Duloxetine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Duloxetine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Duloxetine Market by Type
  1. 4.1 Duloxetine Type Introduction
  2. 4.1.1 60mg Capsules
  3. 4.1.2 40mg Capsules
  4. 4.1.3 30mg Capsules
  5. 4.1.4 20mg Capsules
  6. 4.2 Global Duloxetine Sales Value by Type
  7. 4.2.1 Global Duloxetine Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Duloxetine Sales Value by Type (2021-2032)
  9. 4.2.3 Global Duloxetine Sales Value Share by Type (2021-2032)
5 Duloxetine Market by Application
  1. 5.1 Duloxetine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drug store
  4. 5.2 Global Duloxetine Sales Value by Application
  5. 5.2.1 Global Duloxetine Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Duloxetine Sales Value by Application (2021-2032)
  7. 5.2.3 Global Duloxetine Sales Value Share by Application (2021-2032)
6 Duloxetine Regional Value Analysis
  1. 6.1 Global Duloxetine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Duloxetine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Duloxetine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Duloxetine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Duloxetine Sales Value (2021-2032)
  7. 6.3.2 North America Duloxetine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Duloxetine Sales Value (2021-2032)
  10. 6.4.2 Europe Duloxetine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Duloxetine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Duloxetine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Duloxetine Sales Value (2021-2032)
  16. 6.6.2 South America Duloxetine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Duloxetine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Duloxetine Sales Value Share by Country, 2025 VS 2032
7 Duloxetine Country-level Value Analysis
  1. 7.1 Global Duloxetine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Duloxetine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Duloxetine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Duloxetine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Duloxetine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Duloxetine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Duloxetine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Duloxetine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Duloxetine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Duloxetine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Duloxetine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Duloxetine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Duloxetine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Duloxetine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Duloxetine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Duloxetine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Duloxetine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Duloxetine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Duloxetine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Duloxetine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Duloxetine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Duloxetine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Duloxetine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Duloxetine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Duloxetine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Duloxetine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Duloxetine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Duloxetine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Duloxetine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Duloxetine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Duloxetine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Duloxetine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Duloxetine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Duloxetine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Duloxetine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Duloxetine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Duloxetine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Duloxetine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Duloxetine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Duloxetine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Duloxetine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Duloxetine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Duloxetine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Duloxetine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Duloxetine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Duloxetine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Duloxetine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Duloxetine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Duloxetine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Duloxetine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Duloxetine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Duloxetine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Duloxetine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Duloxetine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Duloxetine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Duloxetine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Duloxetine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Duloxetine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Duloxetine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Duloxetine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Duloxetine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Duloxetine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Duloxetine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Duloxetine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Duloxetine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Duloxetine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Duloxetine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Duloxetine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Duloxetine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Duloxetine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Duloxetine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Duloxetine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Duloxetine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Duloxetine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Duloxetine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Duloxetine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Duloxetine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Duloxetine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Duloxetine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Duloxetine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Duloxetine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Duloxetine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Duloxetine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Duloxetine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Duloxetine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Duloxetine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Duloxetine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Duloxetine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Duloxetine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Duloxetine Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sun Pharma
  8. 8.2.1 Sun Pharma Company Information
  9. 8.2.2 Sun Pharma Business Overview
  10. 8.2.3 Sun Pharma Duloxetine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharma Duloxetine Product Portfolio
  12. 8.2.5 Sun Pharma Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Duloxetine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Duloxetine Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Zydus Pharmaceuticals
  20. 8.4.1 Zydus Pharmaceuticals Company Information
  21. 8.4.2 Zydus Pharmaceuticals Business Overview
  22. 8.4.3 Zydus Pharmaceuticals Duloxetine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zydus Pharmaceuticals Duloxetine Product Portfolio
  24. 8.4.5 Zydus Pharmaceuticals Recent Developments
  25. 8.5 Jiangsu Nhwa Pharmaceutical
  26. 8.5.1 Jiangsu Nhwa Pharmaceutical Company Information
  27. 8.5.2 Jiangsu Nhwa Pharmaceutical Business Overview
  28. 8.5.3 Jiangsu Nhwa Pharmaceutical Duloxetine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Jiangsu Nhwa Pharmaceutical Duloxetine Product Portfolio
  30. 8.5.5 Jiangsu Nhwa Pharmaceutical Recent Developments
  31. 8.6 Torrent Pharmaceuticals
  32. 8.6.1 Torrent Pharmaceuticals Company Information
  33. 8.6.2 Torrent Pharmaceuticals Business Overview
  34. 8.6.3 Torrent Pharmaceuticals Duloxetine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Torrent Pharmaceuticals Duloxetine Product Portfolio
  36. 8.6.5 Torrent Pharmaceuticals Recent Developments
  37. 8.7 MACLEODS
  38. 8.7.1 MACLEODS Company Information
  39. 8.7.2 MACLEODS Business Overview
  40. 8.7.3 MACLEODS Duloxetine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 MACLEODS Duloxetine Product Portfolio
  42. 8.7.5 MACLEODS Recent Developments
  43. 8.8 Lupin
  44. 8.8.1 Lupin Company Information
  45. 8.8.2 Lupin Business Overview
  46. 8.8.3 Lupin Duloxetine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lupin Duloxetine Product Portfolio
  48. 8.8.5 Lupin Recent Developments
  49. 8.9 CSPC Ouyi Pharm
  50. 8.9.1 CSPC Ouyi Pharm Company Information
  51. 8.9.2 CSPC Ouyi Pharm Business Overview
  52. 8.9.3 CSPC Ouyi Pharm Duloxetine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CSPC Ouyi Pharm Duloxetine Product Portfolio
  54. 8.9.5 CSPC Ouyi Pharm Recent Developments
  55. 8.10 Breckenridge
  56. 8.10.1 Breckenridge Company Information
  57. 8.10.2 Breckenridge Business Overview
  58. 8.10.3 Breckenridge Duloxetine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Breckenridge Duloxetine Product Portfolio
  60. 8.10.5 Breckenridge Recent Developments
  61. 8.11 Aurobindo Pharma
  62. 8.11.1 Aurobindo Pharma Company Information
  63. 8.11.2 Aurobindo Pharma Business Overview
  64. 8.11.3 Aurobindo Pharma Duloxetine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Aurobindo Pharma Duloxetine Product Portfolio
  66. 8.11.5 Aurobindo Pharma Recent Developments
  67. 8.12 Apotex
  68. 8.12.1 Apotex Company Information
  69. 8.12.2 Apotex Business Overview
  70. 8.12.3 Apotex Duloxetine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Apotex Duloxetine Product Portfolio
  72. 8.12.5 Apotex Recent Developments
  73. 8.13 Ajanta Pharma
  74. 8.13.1 Ajanta Pharma Company Information
  75. 8.13.2 Ajanta Pharma Business Overview
  76. 8.13.3 Ajanta Pharma Duloxetine Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ajanta Pharma Duloxetine Product Portfolio
  78. 8.13.5 Ajanta Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst